Gut Liver.
2022 Jan;16(1):3-4. 10.5009/gnl210585.
Is Neoadjuvant Therapy Needed in Patients with Resectable Pancreatic Cancer?
- Affiliations
-
- 1Department of Internal Medicine, Pusan National University College of Medicine and Institute, Pusan National University Hospital, Busan, Korea
- KMID: 2524755
- DOI: http://doi.org/10.5009/gnl210585
Abstract
- No abstract available
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer
- Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
- Role of Neoadjuvant Therapy for Borderline Resectable or Locally Advanced Pancreatic Cancer
- Updates of Chemotherapy and Radiotherapy for Pancreatic Cancer
- Updates of Chemotherapy for Pancreatic Cancer
